• Explore /
  • Poster
  • / Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): Results of an a priori interim analysis of a multicenter phase I trial.

Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): Results of an a priori interim analysis of a multicenter phase I trial.

Abstract Poster

Authors

Shearwood McClelland, III

Shearwood McClelland III

Indiana University School of Medicine, Indianapolis, IN

Shearwood McClelland III, Tim Lautenschlaeger , Kevin Shiue , Amy C. Miller , Yong Zang , Kathryn I. Lauer , Nasser H. Hanna , Ryan Rhome , Namita Agrawal , Paul Anthony , Jerry Jeff Jaboin , Blair Murphy , Gordon A. Watson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Brain Metastases

Clinical Trial Registration Number

NCT04047602

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2013)

DOI

10.1200/JCO.2022.40.16_suppl.2013

Abstract #

2013

Poster Bd #

351

Abstract Disclosures

Similar Posters

First Author: Shearwood McClelland III

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Patient reported toxicities: Development and validation of patient-reported symptom measure for lung cancer patients receiving immunotherapy.

Patient reported toxicities: Development and validation of patient-reported symptom measure for lung cancer patients receiving immunotherapy.

First Author: Sandra S. Shaw

First Author: Carolyn Moloney

First Author: Fauzia Riaz